3
Announcements
Trials
Browse
Landscape
Status
Completed
32
Active not recruiting
31
Recruiting
26
Not yet recruiting
9
Terminated
8
Unknown
5
Withdrawn
2
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
EGFR T790M Mutation Positive NSCLC
1
Interventions
nilotinib
4
dabrafenib
4
trametinib
3
regorafenib
3
midostaurin
3
elotuzumab
3
Nivolumab
3
tazemetostat
2
talimogene laherparepvec
2
ceritinib
2
TIC10 compound
2
Suspensions
2
Prednisone
2
Powders
2
Panobinostat
2
Melphalan
2
Lenalidomide
2
Ipilimumab
2
Everolimus
2
Dexamethasone
2
Crizotinib
2
Bortezomib
2
Bevacizumab
2
Axitinib
2
zanubrutinib
1
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
talquetamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
INDUSTRY
×
osimertinib
×
Clear all
NCT02451852
2016-07-14
AZD9291 US Expanded Access Program
AstraZeneca
No longer available